E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33%
Market Cap: 92.2B EUR

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of EPE.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EPE Intrinsic Value
Not Available
E
Base Case Scenario

Fundamental Analysis

Epizyme Inc
F:EPE
US
Biotechnology
Market Cap
94.1B EUR
IPO
May 31, 2013
US
Biotechnology
Market Cap
94.1B EUR
IPO
May 31, 2013
Price
€false
EPS
$false
Company Overview
Loading...
Business Segments
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Significant reliance on Tazemetostat exposes Epizyme to concentrated revenue risk, and any clinical or regulatory setbacks for this lead asset could materially reduce the firm’s prospects.

Bull Theses

Tazemetostat’s successful initial approvals for advanced epithelioid sarcoma and certain follicular lymphoma settings could open the door to broader label expansions and make Epizyme an important player in epigenetic oncology.

Show More Less
How do you feel about EPE?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Epizyme Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Epizyme Inc

Current Assets 186.8m
Cash & Short-Term Investments 144.4m
Receivables 11.2m
Other Current Assets 31.2m
Non-Current Assets 77.3m
PP&E 19.2m
Intangibles 40.8m
Other Non-Current Assets 17.4m
Efficiency

Free Cash Flow Analysis
Epizyme Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Epizyme Inc

Revenue
53m USD
Cost of Revenue
-13m USD
Gross Profit
40.1m USD
Operating Expenses
-236.2m USD
Operating Income
-196.2m USD
Other Expenses
-11.6m USD
Net Income
-207.7m USD
Fundamental Scores

EPE Profitability Score
Profitability Due Diligence

Epizyme Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Exceptional 1-Year Revenue Growth
27/100
Profitability
Score

Epizyme Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

EPE Solvency Score
Solvency Due Diligence

Epizyme Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
42/100
Solvency
Score

Epizyme Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EPE Price Targets Summary
Epizyme Inc

There are no price targets for EPE.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for EPE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest